drugset / Trial / NCT02095314

Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

NCT02095314 ↗

Phase 2/3 Completed 399 enrolled PT Bio Farma
NaSingle-groupOpen-labelPrevention

Summary

Measure antibody persistence prior to booster administration of Pentabio vaccine.

Timeline

Start
2014-03
Primary completion
2014-06
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentavalen Unknown 0.5 ml Intramuscular

Indications

No indication recorded.